A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight (SURMOUNT-2)

This is a study of tirzepatide in participants with type 2 diabetes who have obesity or are overweight. The main purpose is to learn more about how tirzepatide affects body weight.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Obesity, Type 2 Diabetes
What the trial is testing?
Tirzepatide
Could I receive a Placebo?
Yes
Enrollment Goal
938
Trial Dates
Mar 29, 2021 - Apr 10, 2023
How long will I be in the trial?
The study will last about 79 weeks and may include up to 22 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have type 2 diabetes

  • Participants must be overweight or have obesity

Participants Must Not:

  • Participants must not have type 1 diabetes

  • Participants must not have other serious or unstable illnesses

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources

Obesity Research

Click the below button to learn more about obesity research and clinical trials.

Learn More

Diabetes Research

To learn more about diabetes and clinical trials being carried out in this area, visit our Diabetes Research page.

Driving Diversity in Lilly’s clinical trials

Learn how Lilly is working with health care partners to improve diversity in our clinical studies.

Watch the Video

Clinical Trial Participation: What to Expect

A clinical trial is a scientific study. It helps us learn if a new medicine or treatment works and how it works. Clinical trials can also be called clinical research studies. Learn more about clinical research studies and what to expect when taking part in a clinical trial.